Bausch Health Expands Board with Two New Appointments, Boosts Growth Prospects

Bausch Health Companies has appointed Michael Goettler and Sandra Leung to their Board of Directors, expanding the Board to 12 members. Analysts forecast an average target price of $7.08, with an estimated upside of 6.52% from the current price. The company reported revenue of $2.259 billion, up 5% year-over-year, and adjusted EBITDA of $661 million, a decrease of 1% year-over-year.

Bausch Health Companies Inc. (NYSE:BHC) has expanded its Board of Directors to 12 members with the appointment of Michael Goettler and Sandra Leung. The appointments, effective July 22, 2025, are part of a strategic move to strengthen the company's leadership and governance [2].

Michael Goettler, former CEO of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Sandra Leung, former Executive VP and General Counsel of Bristol Myers Squibb, will join the Nominating and Corporate Governance Committee. Both executives bring extensive industry experience and leadership capabilities to the Board [2].

The company reported strong revenue growth of 5% year-over-year to $2.259 billion, and adjusted EBITDA of $661 million, a decrease of 1% year-over-year. Analysts forecast an average target price of $7.08, with an estimated upside of 6.52% from the current price [2].

The appointments of Goettler and Leung signal Bausch Health's commitment to enhancing its strategic direction and strengthening its stakeholder relationships. The additions are expected to provide valuable insights and guidance as the company continues to evolve and expand its global footprint.

References:

[1] https://www.stocktitan.net/news/BHC/bausch-health-announces-the-appointment-of-two-new-members-to-its-qc0122csaadr.html
[2] https://www.stocktitan.net/news/BHC/bausch-health-announces-the-appointment-of-two-new-members-to-its-qc0122csaadr.html